Norcodeine is an opiate analogue that is the N-demethylated derivative of codeine. It has relatively little opioid activity in its own right, but is formed as a metabolite of codeine following ingestion.
Norcodeine is a Schedule I Narcotic controlled substance in the US with the ACSCN of 9309 and zero annual manufacturing quota. The salts in use are the acetate (free base conversion ratio 0.826), hydroiodide (0.662), hydrochloride (0.759), nitrate (0.819), platinichloride (0.582), and sulphate (0.744).
See also
References
Fraser HF, Isbell H, Vanhorn GD (June 1960). "Human pharmacology and addiction liability of norcodeine". The Journal of Pharmacology and Experimental Therapeutics. 129: 172–7. PMID 13824628. /wiki/PMID_(identifier) ↩
Posey BL, Kimble SN (1984). "High-performance liquid chromatographic study of codeine, norcodeine, and morphine as indicators of codeine ingestion". Journal of Analytical Toxicology. 8 (2): 68–74. doi:10.1093/jat/8.2.68. PMID 6716978. /wiki/Doi_(identifier) ↩
"Quotas - 2014". DEA Diversion Control Division. https://www.deadiversion.usdoj.gov/fed_regs/quotas/2014/fr0825.htm ↩